• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Society of Hematology (ASH) 2024

December 7 - 10, 2024

  1. Acalabrutinib
  2. AZD0486
  3. Durvalumab; acalabrutinib
  4. Oncology Unbranded

pdf

Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the nordic lymphoma group NLG-MCL8 (ALTAMIRA) phase II trial

pdf

Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia: Interim analysis of the multicenter, open-label, randomized, phase 3 AMPLIFY trial

pdf

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

pdf

MRD-driven time-limited therapy of acalabrutinib and lenalidomide plus rituximab (ALR) or obinutuzumab (ALO) in patients with treatment-naïve mantle cell lymphoma: Phase 2 trial outcomes with MRD and cfDNA analyses

pdf

Primary endpoint evaluation of a multicenter, phase 2 study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease

pdf

Real-world Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets

pdf

Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study (ChangE)

pdf

High-risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

pdf

Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)

pdf

Efficacy and safety of Acalabrutinib treatment in very old (≥80y) and/or frail patients with Chronic Lymphocytic Leukemia (CLL) – Primary endpoint analysis of the phase II CLL-Frail Trial

pdf

Early Obinutuzumab significantly increases bone marrow undetectable MRD (10-4 sensitivity) (uMRD4) rate when combined with Acalabrutinib and Venetoclax in a randomized phase II trial for treatment naïve CLL

pdf

Acalabrutinib with Rituximab is highly effective first line treatment for elderly patients with mantle cell lymphoma

pdf

Preliminary efficacy and eafety of a phase I/II study of Acalabrutinib, Venetoclax, and Obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma (MAVO)

HTML

Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: 24-month efficacy and safety results from an open-label, multicenter phase 1/2 trial

html

Validation and implementation of flow cytometry based minimal residual disease (MRD) assay for chronic lymphocytic leukemia (CLL) clinical studies

HTML

A real-world comparative analysis of hypertension (HTN) and time to treatment failure (TTF) with acalabrutinib vs ibrutinib in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

html

Baseline characteristics from ARISE study, an Italian non-interventional study assessing the real-world use of Acalabrutinib in the treatment of patients with Chronic Lymphocytic Leukemia (CLL)

html

Real-world effectiveness and safety outcomes of acalabrutinib treatment in patients with relapsed/refractory mantle cell lymphoma

pdf

Evaluation of AZD0486, a novel CD19xCD3 T-Cell engager, in relapsed/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: High complete responses seen in CAR-T–naive and CAR-T–exposed patients

pdf

Escalating Doses of AZD0486, a Novel CD19xCD3 T-cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

pdf

Phase I study with dose expansion of acalabrutinib and durvalumab in primary central nervous system lymphoma

pdf

Pre-clinical Efficacy and Safety of AZD5492: a CD8-guided T Cell Engager for B-Non-Hodgkin Lymphoma Indications

pdf

A phase I study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-ineligible newly diagnosed multiple myeloma

html

Brazilian reality of diffuse large B-Cell lymphoma (BRA – DLBCL): A multicenter retrospective study

html

Development of a high-throughput multiplex immunofluorescence pipeline in Classic Hodgkin Lymphoma whole slide formalin-fixed paraffin-embedded tissue samples

html

Practical considerations in correspondence to emerging regulatory feedback on dose escalation in early hematology clinical development

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice